Professor David Price, FRCGP
Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, UK
Managing Director of Observational and Pragmatic Research Institute, Singapore
Managing Director of Optimum Patient Care, Australia and UK
Professor David Price is founder and head of The Observational and Pragmatic Research Institute (Singapore), an independent, research-driven organisation established to cultivate initiatives, provide evidence and drive quality standards within the growing field of real-life, pragmatic and observational research. This dynamic organisation delivers pragmatic clinical trials and real-life database research across multiple geographies, including territories in the United States, Europe and the Asia-Pacific region, such as Singapore, South Korea, Taiwan, The Philippines, New Zealand, Australia, Japan and China. He is also head of Optimum Patient Care (Australia and UK), a science-based, social enterprise which focuses on disease registries and supporting care in primary and secondary care led by internationally recognised experts in all areas of respiratory medicine.
Professor Price established the Optimum Patient Care Research Database (OPCRD; http://opcrd.co.uk/), one of the largest enhanced healthcare databases holding anonymous data from over 700 general practices and approximately 6.3 million patients in the UK. He currently leads the first International Severe Asthma Registry (ISAR; http://isaregistries.org/) by creating a consortium of world leaders at the forefront of severe asthma research from over 20 countries. His efforts have unified the severe asthma world by creating a vibrant space to exchange ideas and by standardising the data fields across countries, which is enabling data to be pooled and shared.
Professor Price is Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen (UK). He was awarded Fellow of ERS (FERS) in 2016. He is also a member of the World Health Organization (WHO) Allergic Rhinitis and its Impact on Asthma (ARIA) executive committee, the World Allergy Organization (WAO) Committee on Asthma, and the WAO Education Council.
Professor Price was the founding president of the Respiratory Effectiveness Group (http://www.effectivenessevaluation.org/), a not-for-profit, investigator-led initiative which uses an international collaborative approach to explore the optimum role of real-life research in informing clinical guidelines and improving patient care.
Professor Price completed his medical degree at Cambridge University in 1984. He was previously Affiliate Associate Professor in the Department of General Practice at the University of Adelaide, Australia and held an Honorary Chair at the University of East Anglia, UK.
He is extensively involved in respiratory and allergy research; his areas of special interest are the ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, adherence, and patient attitudes to their disease. He has authored more than 490 peer-reviewed publications and is responsible for approximately US$50 million in research and clinical development grants. He is currently Editor-in-Chief of the journal Pragmatic and Observational Research and member of the editorial board of several respiratory journals, including The Lancet Respiratory Medicine.